Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
Date:5/8/2012

al cancer, we remain excited by the prospects of the Zerenex opportunity as a treatment for hyperphosphatemia.  Following two successful short-term Phase 3 studies of Zerenex, in the U.S. and Japan, we look forward to the completion of the Phase 3 clinical programs in the U.S. and Japan by year-end, and the potential New Drug Application filings in the U.S., Europe and Japan within less than  twelve months."  Ron Bentsur, continued, "Our financial position remains strong and we believe that we have sufficient capital to take us beyond the anticipated NDA filings for Zerenex."

The Company will host an investor conference call tomorrow, Wednesday, May 9, 2012, at 8:30am EDT, to discuss the Company's first quarter financial results and provide a business outlook for the remainder of 2012.In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, announced today that ... to support a strong launch of Edwards Lifesciences Foundation,s ... to improve the global communities where its employees live ... corporate giving will exceed $8 million, including more than ...
(Date:11/21/2014)... 2014 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or ... Todd Martensen has been ... role of Chief Commercial Officer, to oversee KLOX,s commercial ... gel for the treatment of chronic and other hard-to-heal ... approved in Europe . Mr. Martensen, ...
(Date:11/21/2014)... , Nov. 20, 2014   Coqui RadioPharmaceuticals Corp. ... first U.S. commercial producer of Molybdenum-99 (Mo-99), is proud ... INVAP to design its Medical Isotope Production ... Mo-99 is the parent isotope of Technetium-99, which is ... In 2012, Congress passed legislation making it a national ...
Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... , ABBOTT PARK, Ill., Dec. 2 Abbott,s Ibis technology ... named one of the top innovations in 2009 by The ... broad range of life science technologies to determine the year,s top ... online at www.the-scien t ist.com/top10innovations . ...
... , NEW YORK, Dec. 2 ... veteran attorneys, led by Neil H. Ekblom, LeClairRyan,s medical ... the New York market. Mr. Ekblom, a former state ... , The New York team adds to an existing ...
Cached Medicine Technology:Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist 2Neil H. Ekblom and Medical Malpractice Defense Team Join LeClairRyan 2Neil H. Ekblom and Medical Malpractice Defense Team Join LeClairRyan 3
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 ... for the dental practice. It includes everything needed to ... , Procedure Coding with CDT , CDT 2015 codes ... from January 1, 2014 - December 31, 2014. Dental ... procedures and services on dental claims. There are significant ...
(Date:11/21/2014)... 21, 2014 TopConsumerReviews.com recently awarded ... industry leader in the relief of depression ... feelings of sadness and depression each year and ... choices. Often, prescription drugs can produce worse side ... are expensive and require regular follow-up visits with ...
(Date:11/21/2014)... FL (PRWEB) November 21, 2014 According ... issued on June 11th, 2014, the inflating system ... rupture when the airbag inflates. The force of inflation ... shrapnel, and the metal shards may pierce the airbag’s ... vehicle’s cabin. , According to a Bloomberg Business ...
(Date:11/21/2014)... 2014 M3 Global Research , a ... panel, today announced two important leadership changes to help accelerate ... President of Market Research, Americas and the promotion of Anton ... , Ms. DasGupta joined M3 in 2011 and has held ... of Sales. Roni has over 17 years of experience ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. ... the wall of a still-beating heart has the potential to ... to a new study. Heart patients who received the ... to walk hundreds of feet farther during a six-minute walk ... of the cardiovascular division at Washington University School of Medicine ...
Breaking Medicine News(10 mins):Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Gel Implant Might Help Fight Heart Failure 2Health News:Gel Implant Might Help Fight Heart Failure 3
... Health experts have warned that the growing menace of ... contained// otherwise there would be a global health crisis. ... safety in the developed and developing world," said Jo ... the low penalties for counterfeits are shocking. Countering supply ...
... which they say can be controlled by the power ... Kamitani and colleagues, mimics the movements of a person's ... (fMRI) of their brain activity, reported the online edition ... Computational Neuroscience Laboratories in Kyoto and from the Honda ...
... the San Francisco VA Medical Center and the University of California, San Francisco, poor literacy ... two times as likely to have poor health and poor health care access in people ... ... Elders with limited literacy, which the researchers define ...
... was suspended a she removed the properly functioning kidney from ... him guilty and suspended him for a period of 12 ... the French surgeon, Mr Blanchard’s conduct was inappropriate, unprofessional and ... ,He said that he had not read the patient's ...
... of the study, James Raftery, a professor health technology assessment ... decisions//. The National Institute for Health and Clinical Excellence (NICE) ... in 1999 and given the task of getting the best ... the NHS in England and Wales and recommends whether they ...
... to GSVM medical college in Kanpur remained affected today ... elite educational institutions entered the 11th day here. // ... the protest against Centre's decision to implement 27 per ... representatives of agitating doctors said., ,However, sources at ...
Cached Medicine News:Health News:Lower Literacy Puts Poor Health In Aging 2Health News:Lower Literacy Puts Poor Health In Aging 3
... need to add individual components for individual ... trauma indications. Made of an innovative composite ... fixators, only much lighter. This means it's ... more comfortable for the patient. ,Comes pre-assembled, ...
... osmolar ionic dimer. Each milliliter contains ... mg of ioxaglate sodium and 0.10 ... a stabilizer. The solution contains 3.48 ... and provides 32% (320 mg/mL) organically ...
... (iopamidol injection) is a safe and effective ... clinical experience since 1986. Worldwide, more ... been administered. Indicated for a wide ... flexibility by providing a wide range of ...
... is a formulation of iopamidol in ... oral administration or, where necessary, by ... improvement in the radiological exploration of ... contrast media. Thanks to its low ...
Medicine Products: